Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in San Antonio, Texas and currently employs 89 full-time employees. The company went IPO on 2013-07-24. The firm was previously a contract development and manufacturing organization.

Industry: Pharmaceutical Preparations Peers: Applied Therapeutics, Inc. Cidara Therapeutics, Inc. Quince Therapeutics Inc Sellas Life Sciences Group Inc Galera Therapeutics Inc IN8bio Inc Mustang Bio Inc TAO Synergies Inc Rubius Therapeutics, Inc.